Malaria Information and Prophylaxis, by Country [C]

The information presented in this table is consistent 1 with the information in the CDC Health Information for International Travel (the “Yellow Book”).

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
 
Country Areas with Malaria Drug Resistance2 Malaria Species3 Recommended Chemoprophylaxis4 Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries
Cambodia Present throughout the country. None or negligible transmission in the cities of Phnom Penh and Siem Reap, and at the main temple complex at Angkor Wat. Chloroquine

Mefloquine

P. vivax 80%; P. falciparum 20%; P. knowlesi 7 rare Atovaquone-proguanil, doxycycline, or tafenoquine5.
Cameroon All Chloroquine Primarily P. falciparum. Less commonly, P. malariae, P. ovale, or P. vivax Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Canada None Not Applicable Not Applicable Not Applicable
Canary Islands (Spain) None Not Applicable Not Applicable Not Applicable
Cape Verde No indigenous cases reported since 2018. Previously, rare cases on Santiago (São Tiago) Island and Boa Vista Island. Previously, chloroquine Previously, primarily P. falciparum None (mosquito avoidance only)6
Cayman Islands (U.K.) None Not Applicable Not Applicable Not Applicable
Central African Republic All Chloroquine Primarily P. falciparum. Less commonly, P. malariae, P. ovale, or P. vivax Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Chad All Chloroquine Primarily P. falciparum. Less commonly, P. malariae, P. ovale, or P. vivax Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Chile None Not Applicable Not Applicable Not Applicable
China None Not Applicable Not Applicable Not Applicable
Christmas Island (Australia) None Not Applicable Not Applicable Not Applicable
Cocos (Keeling) Islands (Australia) None Not Applicable Not Applicable Not Applicable
Colombia All areas <1,700 m (5,577 ft). None in Bogotá, Cartagena, and Medellin. Chloroquine P. falciparum 50%,

P. vivax 50%

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Comoros All Chloroquine Primarily P. falciparum. P. malariae and P. vivax rare Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Congo, Republic of the (Congo-Brazzaville) All Chloroquine Primarily P. falciparum. Less commonly, P. malariae, P. ovale, or P. vivax Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Cook Islands (New Zealand) None Not Applicable Not Applicable Not Applicable
Costa Rica Some transmission in Alajuela Province near the border with Nicaragua.

Rare to no transmission in other parts of the country

None P. vivax 78%,
P. falciparum
22%
Alajuela Province near the border with Nicaragua: Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, or tafenoquine.
All other areas: None (mosquito avoidance only.)6
Côte d’Ivoire All Chloroquine Primarily P. falciparum. Less commonly, P. malariae, P. ovale, or P. vivax Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine5
Croatia None Not Applicable Not Applicable Not Applicable
Cuba None Not Applicable Not Applicable Not Applicable
Cyprus None Not Applicable Not Applicable Not Applicable
Czech Republic None Not Applicable Not Applicable Not Applicable

1. Factors that affect local malaria transmission patterns can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection. Information in these tables is updated regularly.
2.  Refers to P. falciparum malaria unless otherwise noted.
3. Estimates of malaria species are based on best available data from multiple sources. Where proportions are not available, the primary species and less common species are identified.
4. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
5. Primaquine and tafenoquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Before prescribing primaquine or tafenoquine, patients must be screened for G6PD deficiency using a quantitative test.
6. Mosquito avoidance includes applying topical mosquito repellant, sleeping under an insecticide treated bed net, and wearing protective clothing (e.g., long pants and socks, long sleeve shirt). For additional details on mosquito avoidance, see: https://www.cdc.gov/malaria/travelers/index.html
7. P. knowlesi is a malaria species with a simian host (macaque). Human cases have been reported from most countries in Southeast Asia and are associated with activities in forest or forest-fringe areas. This species of malaria has no known resistance to antimalarials.

Page last reviewed: November 3, 2021